Molecular structure of Bicalutamide, CAS Number: 90357-06-5
Bicalutamide (CAS 90357-06-5)
See product citations (27)
Alternate Names:
Casodex; N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methylpropanamide
Application:
Bicalutamide is an androgen receptor inhibitor useful in prostate cancer research
CAS Number:
90357-06-5
Purity:
≥98%
Molecular Weight:
430.37
Molecular Formula:
C18H14F4N2O4S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Bicalutamide is a compound that is of particular interest in biochemical research focused on androgen receptor (AR) signaling pathways. In various studies, it is used to investigate the effects of AR antagonism on cellular proliferation, especially in contexts where androgens play a significant role in cell growth regulation. The compound serves as a tool to comprehend the molecular dynamics of hormone-receptor interactions and the changes in gene expression that follow AR blockage. Bicalutamide′s role in protein binding and the conformational changes within the AR that it induces are also subjects of investigation, providing insights into the design of selective receptor modulators. Additionally, research involving bicalutamide includes the study of its influence on signal transduction pathways and its impact on cellular differentiation and apoptosis in certain cellular models.
Bicalutamide (CAS 90357-06-5) References
- Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis. | Cui, Y., et al. 2014. Urol Int. 93: 152-9. PMID: 24603064
- Testosterone/bicalutamide antagonism at the predicted extracellular androgen binding site of ZIP9. | Bulldan, A., et al. 2017. Biochim Biophys Acta Mol Cell Res. 1864: 2402-2414. PMID: 28943399
- Bicalutamide enhances fodrin-mediated apoptosis through calpain in LNCaP. | Lee, J., et al. 2018. Exp Biol Med (Maywood). 243: 843-851. PMID: 29860890
- Effect of Bicalutamide on the proliferation and invasion of human triple negative breast cancer MDA-MB-231 cells. | Kong, Y., et al. 2020. Medicine (Baltimore). 99: e19822. PMID: 32332626
- Bicalutamide Elicits Renal Damage by Causing Mitochondrial Dysfunction via ROS Damage and Upregulation of HIF-1. | Chen, KC., et al. 2020. Int J Mol Sci. 21: PMID: 32403414
- Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know. | Carvalho, RM., et al. 2022. J Cosmet Dermatol. 21: 4171-4175. PMID: 35032336
- Bicalutamide may enhance kidney injury in diabetes by concomitantly damaging energy production from OXPHOS and glycolysis. | Peng, CC., et al. 2022. Chem Biol Interact. 356: 109858. PMID: 35151640
- Bicalutamide, an androgen receptor antagonist, effectively alleviate allergic rhinitis via suppression of PI3K-PKB activity. | Zhang, Y., et al. 2023. Eur Arch Otorhinolaryngol. 280: 703-711. PMID: 35831673
- Effect of Bicalutamide Combined with Docetaxel on Serum PSA and VEGF Levels in Patients with Advanced Prostate Carcinoma. | Guo, Z., et al. 2022. Dis Markers. 2022: 4506350. PMID: 36033830
- The ERα-NRF2 signalling axis promotes bicalutamide resistance in prostate cancer. | Tian, L., et al. 2022. Cell Commun Signal. 20: 178. PMID: 36376959
- Bicalutamide Anticancer Activity Enhancement by Formulation of Soluble Inclusion Complexes with Cyclodextrins. | De Gaetano, F., et al. 2022. Biomolecules. 12: PMID: 36421730
- Bicalutamide and Trehalose Ameliorate Spinal and Bulbar Muscular Atrophy Pathology in Mice. | Galbiati, M., et al. 2023. Neurotherapeutics. 20: 524-545. PMID: 36717478
- An overview of animal toxicology studies with bicalutamide (ICI 176,334). | Iswaran, TJ., et al. 1997. J Toxicol Sci. 22: 75-88. PMID: 9198005
Inhibitor of:
17β-HSD11, 17β-HSD14, 17β-HSD2, 17β-HSD6, 4921511H03Rik, 4930458L03Rik, 4933421E11Rik, 9230110F15Rik, Abp ε, AKR1D1, Androgen Receptor, AR, ARA54, ARA70, ARL13B, ARL3, BCAS4, BOULE, BPY2, C10orf12, C1orf111, C6orf10, CEACAM5, Choriogonadotropin β, DHRS7, DMRTC2, EG436008, EG639025, EG665615, EG667693, EHZF, Forkhead box N (FOXN), FOXL2, FOXN1, GCM2, Glycodelin, Gm597, GREB1, HCG3, HoxB13, Kap, LCOR, LRIF, MAGE-H1, MBPH, MEA-1, MISR II, MUP11, NGEP, Olfr350, Olr208, Olr515, Olr690, Olr714, Ott, OTTMUSG00000008394, Pma, PMEPA1, Prl2c1, probasin, Prostate Tumor Marker, PSA, PSCA, PSGR, PXR, Rhox2, Rhox4, Rhox8, RHOXF2, SAF-B2, SLY, SMR2, SMR3A, SPANX-A, SPANX-N3, SPATA12, SPATA16, SPATA25, SPATA32, SPEER-2, TCP-11, Testosterone, TEX13B, TEX30, TLE3, TSARG1, TSARG6, Tsx, UROC28, UXT, Vmn2r23, WDR77, Zinc-finger protein (ZNF), ZNF140, ZNF318, and ZNF703.Activator of:
ARA70, DD3, Erg, GAGE3, Gonadotropin β, SK1, and SRC-1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Bicalutamide, 100 mg | sc-202976 | 100 mg | $42.00 | |||
Bicalutamide, 500 mg | sc-202976A | 500 mg | $146.00 |